Carregant...
Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies
Cemiplimab, a human monoclonal antibody targeting programmed cell death-1 (PD-1) receptor, demonstrated antitumor activity in patients with advanced malignancies and a safety profile comparable to other anti–PD-1 therapies. This population pharmacokinetics (PopPK) analysis of cemiplimab included 11,...
Guardat en:
| Publicat a: | J Pharmacokinet Pharmacodyn |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer US
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8225544/ https://ncbi.nlm.nih.gov/pubmed/33728546 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10928-021-09739-y |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|